The 2024-2025 mRNA COVID-19 vaccine provided moderate protection against severe outcomes, including hospitalizations and ED visits.
A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.
Hidden in volcanic lakes and deep-sea vents, scientists have discovered tough new DNA-binding proteins built to survive extreme conditions. After scanning huge genetic databases, researchers found ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The constant emergence of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Nearly one in four cases of hyposmia were severe for ...
Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. Pune, a metropolitan city in western India, where this study ...
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...
This study analyzed the immunological mechanisms underlying the elicitation of broadly neutralizing antibodies (bnAbs) by a severeacute respiratory syndrome coronavirus 2 (SARS-CoV-2) bivalent vaccine ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results